Steward Partners Investment Advisory LLC cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) by 60.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the company’s stock after selling 3,000 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Mirum Pharmaceuticals were worth $44,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $606,000. Integral Health Asset Management LLC acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $1,595,000. Congress Wealth Management LLC DE acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $160,000. Raymond James Financial Services Advisors Inc. increased its holdings in Mirum Pharmaceuticals by 6.6% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 25,322 shares of the company’s stock valued at $404,000 after purchasing an additional 1,574 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $409,000. 87.68% of the stock is owned by institutional investors and hedge funds.
Mirum Pharmaceuticals Stock Up 11.8 %
NASDAQ:MIRM opened at $26.05 on Friday. Mirum Pharmaceuticals, Inc. has a 12-month low of $12.82 and a 12-month high of $28.65. The firm has a market capitalization of $829.30 million, a P/E ratio of -11.53 and a beta of 1.44. The stock’s fifty day simple moving average is $22.48 and its 200-day simple moving average is $22.69.
Wall Street Analyst Weigh In
MIRM has been the subject of a number of recent analyst reports. SVB Leerink raised their price target on Mirum Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, May 24th. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $64.00 to $69.00 and gave the company a “buy” rating in a research note on Monday, May 23rd. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $51.80.
Insiders Place Their Bets
In other Mirum Pharmaceuticals news, major shareholder James E. Flynn sold 38,478 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $25.01, for a total transaction of $962,334.78. Following the transaction, the insider now directly owns 1,540,190 shares in the company, valued at $38,520,151.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 33.27% of the company’s stock.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- 3 Hotel Stocks to Consider Checking into After Earnings
- How Does Freeport McMoran Inc Compare to Its Sector Competitors?
- Can FuelCell Energy Surge Higher This Year?
- Is It Time to Take a Ride on Cedar Fair Stock?
- Time To Take A Serious Look At Nikola Stock As Production Starts
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.